Skip to main content
← All verified funding
Tier AUS

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

National Institutes of Health

Sign in and complete your Funding Passport to see whether you qualify — a transparent, rule-based verdict, not a black box.

Sign In

About this opportunity

NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Required documents

The official source lists no specific documents here — confirm requirements before applying.

Source & verification trail

First retrieved
November 20, 2026
Last verified
November 20, 2026
Content fingerprint
758ada0b9dd5928b…